Jeff Ellis, PharmD, MS

GSK
Canton, MI, United States

Health economics and outcomes researcher.

Presentation(s):

• 1533: Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US

  Monday, October 27, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): GlaxoSmithKlein(GSK): Employee (Ongoing)

• 1534: Rapid Oral Glucocorticoid Discontinuation or Dose Reduction Among US Patients with SLE Receiving Belimumab in a Real-World Setting

  Monday, October 27, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): GlaxoSmithKlein(GSK): Employee (Ongoing)

• 2453: Belimumab Is Associated with Lower Risk of Progression to LN Compared with Standard of Care in Patients with SLE

  Tuesday, October 28, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): GlaxoSmithKlein(GSK): Employee (Ongoing)